Tysabri’s PML Risk Quantified In Revised Label; Can Added Certainty Add Scripts?
This article was originally published in The Pink Sheet Daily
Multiple sclerosis and Crohn’s disease patients with anti-JC virus antibodies who have previously taken other immunosuppressants have a 1.1% risk of developing the deadly neurological condition after taking Biogen Idec /Elan’s Tysabri for more than two years.
You may also be interested in...
Judge finds Tysabri label warnings about brain infection were adequate and that there is 'clear evidence' FDA would not have approved a labeling change.
The specter of Tysabri and its restrictive REMS loomed over the review of Takeda’s Entyvio, making for an unusually high level of communication and discussion from Phase II until late in the review cycle – a tally that includes 14 pre-BLA face-to-face meetings between FDA and the sponsor, as well as two advisory committee reviews and two turns before FDA’s REMS Oversight Committee.
Deadly brain disease casts shadow over a quarter in which the company reports progress on new launches, including hemophilia, but PML occurred in only one in 100,000 treated and experience suggests risk can be managed.